Financial Data and Key Metrics Changes - Nurtec ODT achieved fourth quarter net revenues of approximately $35 million, representing an increase of over 98% from the third quarter [7][27] - Non-GAAP adjusted net loss for Q4 2020 was $161.7 million or $2.69 per share, compared to a loss of $124.4 million or $2.38 per share for the same period in 2019 [29] - Cash, marketable securities, and restricted cash totaled $357.4 million as of December 31, 2020, with immediate access to an additional $225 million from a debt facility [30] Business Line Data and Key Metrics Changes - Nurtec ODT has achieved over 450,000 prescriptions with more than 89% commercial coverage [7][8] - SG&A expenses for Q4 2020 on a non-GAAP basis were $114 million, an increase of $47.2 million from the prior year, reflecting investments in the launch of Nurtec [28] Market Data and Key Metrics Changes - The oral CGRP class is experiencing rapid growth, with Nurtec positioned to capture a significant share of the market [34] - Approximately 96% of neurologists perceive Nurtec ODT as an advancement over triptans, with nearly half anticipating it as their preferred acute migraine therapy [35] Company Strategy and Development Direction - The company aims to maximize patient and shareholder value by executing on the Nurtec launch and expanding its indications to include prevention of migraine and other pain-related disorders [9][10] - Biohaven is focused on establishing Nurtec as the first dual-acting migraine therapy for both acute and preventive treatment in one pill, aiming to simplify the treatment paradigm [11][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future growth of Nurtec, anticipating continued market expansion and multiple pivotal trial readouts over the next year [60] - The company is preparing for a potential FDA decision on the approval of Nurtec for prevention by the end of Q2 2021 [42] Other Important Information - Biohaven's pipeline includes intranasal zavegepant, which is expected to file as the first intranasal CGRP antagonist for ultra-rapid treatment of migraine [23] - The company is also exploring non-migraine indications, including psoriasis and asthma, as part of its CGRP franchise expansion [47] Q&A Session Summary Question: Current situation with Nurtec in terms of persistence - Management indicated that refill rates for Nurtec align with expected usage based on migraine frequency, supporting the prevention strategy [64] Question: Insights on sNDA for prevention and EMEA filing - Management noted that they have not received negative comments from the mid-cycle review, which is seen as encouraging for the dual-acting indication in Europe [66] Question: Trends in sales force engagement and authorizations - Management reported that clinician offices are reopening, leading to increased patient access and engagement, which is expected to positively impact sales [70] Question: Impact of patient deductibles and reauthorizations on Q1 - Management explained that the reset of patient deductibles and prior authorizations is a standard occurrence at the beginning of the year, affecting gross-to-net dynamics [76] Question: Lifecycle extension indications for Nurtec - Management expressed excitement about lifecycle management opportunities, including pediatric indications, which are expected to provide significant upside potential [88]

March 1, 2021 4th Quarter 2020 Earnings Ellie, living with migraine © 2021 Biohaven Pharmaceuticals. All rights reserved. NYSE:BHVN Agenda Opening Remarks | Cliff Bechtold, M.S. Chief Operating Officer Quarter Summary and Year in Review | Vlad Coric, M.D. Chief Executive Officer 4Q20 and 2020 Year-End Financial Results | Jim Engelhart, C.P.A. Chief Financial Officer Commercial Events | BJ Jones, M.B.A. Chief Commercial Officer Migraine and Common Disease R&D Update | Elyse Stock, M.D. Chief Medical Officer ...

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants | --- | |------------------------------------------| | | | Cliff Bechtold - Chief Operating Officer | | Vlad Coric - Chief Executive Officer | | Jim Engelhart - Chief Financial Officer | | BJ Jones - Chief Commercial Officer | | Elyse Stock - Chief Medical Officer | | Conference Call Participants | | Paul Choi - Goldman Sachs | | Tyler Van Buren - Piper Sandler | | Ken C ...

Ellie, living with migraine 3rd Quarter 2020 Earnings November 9, 2020 © 2020 Biohaven Pharmaceuticals. All rights reserved. NYSE:BHVN Cliff Bechtold, M.S. | Chief Operating Officer Opening Remarks Agenda 3 Opening Remarks | Cliff Bechtold, M.S. Chief Operating Officer Quarter Summary and Recent Events | Vlad Coric, M.D. Chief Executive Officer 3Q20 Financial Results | Jim Engelhart, C.P.A. Chief Financial Officer Commercial Events | BJ Jones, M.B.A. Chief Commercial Officer Migraine and Common Disease R&D ...

Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Q2 2020 Earnings Conference Call August 10, 2020 8:00 AM ET Company Participants Clifford Bechtold - COO Vladimir Coric - CEO & Director James Engelhart - CFO & Treasurer William Jones - Chief Commercial Officer, Migraine & Common Diseases Elyse Stock - Chief Medical Officer Conference Call Participants Paul Choi - Goldman Sachs Group Charles Duncan - Cantor Fitzgerald & Co. Ken Cacciatore - Cowen and Company Laura Chico - Wedbush Securities Timothy Lu ...

neuroinnovation Meeting Patient Needs Growing Value INVESTOR PRESENTATION | AUG 2020 NYSE: BHVN © 2020 Biohaven Pharmaceuticals Inc. All rights reserved. Disclaimer This presentation contains forward-looking statements within the meaning of "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995, including: statements about Biohaven Pharmaceutical Holding Company Ltd. (The "Company") and our plans to develop and commercialize our product candidates, our planned clinical trials for o ...

Financial Performance - Biohaven reported $9.7 million in net product revenue for Nurtec ODT in Q2 2020[7, 16] - As of June 30, 2020, Biohaven had $263.9 million in cash, including restricted cash[15] - Biohaven secured access to over $700 million in capital[15] - Additional $525 million cash received or immediately available for draw on close of $950 million Sixth Street & RPI financings in August 2020[15] Commercial Success of Nurtec ODT - Nurtec ODT achieved a 52.6% New Brand Rx market share[7, 9, 38] - Nurtec ODT has 83% commercial coverage, representing 141 million covered lives[7, 9, 22, 38] - Nurtec ODT experienced a 22% average weekly TRx volume growth[7, 38] R&D Pipeline and Regulatory Milestones - Biohaven plans to file an sNDA for Migraine prevention in 2H2020, with potential approval in 1H2021[13] - A PMDA meeting is scheduled for Migraine acute/prevention, with a Europe filing planned for 1Q[13] - Filing for Zavegepant (intranasal) for migraine is expected in 4Q, with potential approval in 2022[13]

INDEPENDENCI FROM MIGRAINI Please join Biohaven for an informative Investor and Clinician dinner as leading experts discuss the advancement of the Biohaven NOJECTION™ CGRP antagonist platform. TIME 6:30PM Registration 7:00PM Presentation DATE Tuesday, May 7th, 2019 LOCATION The Rittenhouse Hotel 210 W. Rittenhouse Square Ballroom North, Philadelphia, PA Guest Speakers: Richard Lipton, MD Albert Einstein College of Medicine Montefiore Headache Center David Kudrow, MD California Medical Clinic for Headache Je ...